|
Current guidelines recommend the drugs for everyone with peripheral artery disease, regardless of the need for surgery.
The Dutch study was partially funded by Swiss drug maker Novartis, which makes and supplied Lescol, also known as fluvastatin. Poldermans has received grants and consulting fees from Novartis; two other researchers have received fees and grants from medical companies.
Other statins on the market would likely achieve a comparable effect, said Dr. Alan T. Hirsch, director of the vascular medicine program at the Minneapolis Heart Institute and a spokesman for the American Heart Association. He said statins aren't being used enough in people with peripheral artery disease, and he hopes the study draws attention to their benefits at the time of surgery, as well as throughout the lifetime of the patient.
"A statin is a seat belt when you drive a damaged artery," he said.
___
On the Net:
New England Journal: http://www.nejm.org/
[Associated
Press;
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Community |
Perspectives
|
Law & Courts |
Leisure Time
|
Spiritual Life |
Health & Fitness |
Teen Scene
Calendar
|
Letters to the Editor